Form 4: Cingulate Inc. CEO Acquires Stock Options

Cingulate Inc.'s CEO, Shane J. Schaffer, acquired stock options for 57,323 shares on March 4, 2024, according to a Form 4 filing with the SEC.

Summary

• On March 4, 2024, Shane J. Schaffer, the CEO of Cingulate Inc., acquired stock options for 57,323 shares.
• The exercise price of these options is $1.18.
• The options vest with 50% vesting on the six-month anniversary of the grant date, and the remaining shares vesting in substantially equal monthly installments over the following 30-month period.
• The options expire on March 4, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it can signal confidence from the executive in the company's future.

Positives

• The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• The vesting schedule of 50% after six months and the remainder over 30 months is fairly typical.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation plans.

Key Dates

Keywords

stock options, Cingulate Inc., SEC Form 4, Shane J. Schaffer, executive compensation, beneficial ownership